Stay updated on SBRT-Immunotherapy in Early Lung Cancer: Clinical Trial
Sign up to get notified when there's something new on the SBRT-Immunotherapy in Early Lung Cancer: Clinical Trial page.

Latest updates to the SBRT-Immunotherapy in Early Lung Cancer: Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe study has shifted from a multi-centre phase II design to a single arm phase Ib/II study of nivolumab administered after SBRT for early stage non-small cell lung cancer (NSCLC). Additionally, the principal investigator has changed to Merina Ahmed from the Royal Marsden NHS Foundation Trust.SummaryDifference53%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.8%
Stay in the know with updates to SBRT-Immunotherapy in Early Lung Cancer: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT-Immunotherapy in Early Lung Cancer: Clinical Trial page.